- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:00 | Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO | 192 | PR Newswire | CHENGDU, China, April 13, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results... ► Artikel lesen | |
| SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| Do | SKB BIO-B (06990): DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER | - | HKEx | ||
| Mi | SKB BIO-B (06990): INSIDE INFORMATION GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION BY THE COMPANY | - | HKEx | ||
| 02.04. | Kelun-Biotech steigert Umsatz 2025 - Hohe Investitionen belasten Ergebnis | 1 | Investing.com Deutsch | ||
| 02.04. | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Drop In Full Year Profit | - | RTTNews | ||
| 27.03. | SKB BIO-B (06990): INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANY | 1 | HKEx | ||
| 26.03. | BofAS Raises TP for Kelun-Biotech to HKD523.3, Upgrades to 'Buy' Rating | 3 | AASTOCKS | ||
| 26.03. | CMBI Raises TP of Kelun-Biotech to HKD507.11 as Commercialization Begins | 3 | AASTOCKS | ||
| 24.03. | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB103 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 2 | HKEx | ||
| 24.03. | Kelun-Biotech Announced 2025 Annual Results: Multiple Products Successfully Launched With Tiered Pipeline Ready For Take-off | 448 | PR Newswire | Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximat ely RMB1478.78 mill ion, representing a year-on-year increase.
... ► Artikel lesen | |
| 23.03. | SKB BIO-B (06990): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 18.03. | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT STUDY RESULTS FROM CORE PRODUCT SACITUZUMAB TIRUMOTECAN (SAC-TMT) AT 2026 ELCC | 1 | HKEx | ||
| 11.03. | SKB BIO-B (06990): NOTICE OF BOARD MEETING | - | HKEx | ||
| 10.03. | SKB BIO-B (06990): CONTINUING CONNECTED TRANSACTION AUXILIARY PROMOTIONAL SERVICES FRAMEWORK AGREEMENT | - | HKEx | ||
| 09.03. | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB575 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 1 | HKEx | ||
| 06.02. | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (SAC-TMT) APPROVED FOR MARKETING FOR FOURTH INDICATION BY THE ... | 2 | HKEx | ||
| 23.01. | SKB BIO-B (06990): SUPPLEMENTARY ANNOUNCEMENT CONTINUING CONNECTED TRANSACTION 2026 R&D-RELATED GOODS FRAMEWORK AGREEMENT | 1 | HKEx | ||
| 16.01. | SKB BIO-B (06990): CONTINUING CONNECTED TRANSACTION 2026 R&D-RELATED GOODS FRAMEWORK AGREEMENT | - | HKEx | ||
| 07.01. | SKB BIO-B (06990): TERMINATION OF DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION FOR WEALTH MANAGEMENT PRODUCT | - | HKEx | ||
| 06.01. | SKB BIO-B (06990): DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS | - | HKEx |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,630 | +0,79 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| EVOTEC | 5,230 | +11,28 % | Evotec nominiert ehemaligen Bayer-Manager als Aufsichtsratschef | Evotec SE hat Dieter Weinand als Kandidaten für den Vorsitz des Aufsichtsrats nominiert. Die Hauptversammlung am 11. Juni 2026 soll über seine Wahl abstimmen. Weinand war zuvor unter anderem Vorstandsmitglied... ► Artikel lesen | |
| MODERNA | 43,460 | +0,84 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| BIONTECH | 82,45 | +0,24 % | BioNTech SE: BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs | Trastuzumab Pamirtecan, ein innovativer gegen HER2 gerichteter Antikörper-Wirkstoff-Konjugat-Kandidat, erreichte den primären Wirksamkeitsendpunkt in einer Phase-2-Kohorte bei stark vorbehandelten Patientinnen... ► Artikel lesen | |
| MAPLIGHT THERAPEUTICS | 26,290 | 0,00 % | MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst | ||
| KINIKSA PHARMACEUTICALS | 47,250 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,290 | +1,63 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | |
| ARCELLX | 114,88 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 3,680 | +14,82 % | Morning Market Movers: Avanos Medical, Sana Biotechnology, Credo Technology Group, Bloom Energy See Big Swings | BEIJING (dpa-AFX) - At 7:30 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BB BIOTECH | 50,30 | -0,98 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| VALNEVA | 2,689 | +1,63 % | EILMELDUNG bei Valneva: Das Signal das die meisten Anleger noch nicht kennen - Was ich konkret unternommen habe | ||
| ARCUS BIOSCIENCES | 22,380 | 0,00 % | Arcus Biosciences And Gilead Discontinue Phase 3 STAR-221 Study In Cancer Due To Futility | FOSTER CITY (dpa-AFX) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Friday the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead... ► Artikel lesen | |
| BICARA THERAPEUTICS | 22,140 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,690 | -11,80 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| VOR BIOPHARMA | 15,310 | -4,13 % | Stifel reiterates Vor Biopharma stock rating on drug potential |
Das Unternehmen SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.